NEW YORK (GenomeWeb News) - Rules-Based Medicine today said that its Psynova Neurotech subsidiary will collaborate with Roche on the development and commercialization of diagnostic assays to aid in the development of new schizophrenia treatments.
Under the exclusive research and licensing deal, Roche will contract Psynova to identify protein biomarkers that have utility in prognosis of disease progression and predicting or monitoring the efficacy and safety of a compound from Roche's central nervous system pipeline. Psynova said that it will use its schizophrenia biomarker panels, CNS disease database, and access to RBM's DiscoveryMAP technology to identify a specific biomarker signature that could serve as a companion diagnostic.
Companion diagnostics will be developed either by Psynova and RBM or independently by Roche, which would result in milestone and royalty payments to Psynova.
Financial and further terms of the collaboration were not disclosed.